Navigation Links
Products containing specific probes for detecting alternative splice forms protected

ExonHit Therapeutics, today announced the grant of a major patent, US # 6,881,571, by the United States Patent and Trademark Office on microarray products allowing the specific detection of mRNAs produced by alternative splicing, covering microarrays optimised for the discovery of alternative RNA splicing events. The patent protects the probe configuration of a unique set of five oligonucleotides for the detection of each splice variant. There are many applications for this patent, including drug discovery, diagnostics, and compound screenings for efficacy or toxicity as well as screening patients for potential efficacy of therapeutics.

Alternative RNA Splicing is a critical step in the expression of most genes, which can result in the expression of several mRNAs encoding proteins with different functions from a single gene. Splicing events are implicated in numerous pathologies and can be altered by various stress events such as virus, toxic agents, and drug exposure.

The genome-wide patented probe configuration described in the patent is the basis for the microarrays in ExonHit's SpliceArray product line launched earlier this year. The genome profiling market is rapidly growing, and SpliceArrays are the only commercially available microarrays designed to detect alternative splicing. Current SpliceArray products include GPCR, Ion Channel, and Nuclear Receptor family SpliceArrays, as well as custom design services. An Apoptosis and Cytokine gene family array will be launched in the coming months. SpliceArrays are manufactured for ExonHit by Agilent Technologies.

The granting of this patent solidifies ExonHit's leadership in the field of expression profiling and positions the company as the only partner for the conception or use of gene profiling microarrays that include alternative RNA splicing. "The granting of these claims build on the company's core assets further expanding our IP position in the field of gene expression and profiling," sta ted Bruno Tocque, President and CEO, ExonHit Therapeutics. "This is a significant event for ExonHit as we have been quite successful in leveraging strategic assets in multiple arenas, including the therapeutic, diagnostic and research tool markets ?areas in which these claims will further increase our market share."


'"/>

Source:ExonHit


Related biology news :

1. Metal-containing compounds show promise as HIV weapon
2. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
3. Rapid response was crucial to containing the 1918 flu pandemic
4. Scientists generate patient-specific stem cells, Science study says
5. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
6. Eating, body weight regulated by specific neurons
7. Tool developed to silence genes in specific tissues using RNAi
8. Gene-specific Ebola therapies protect non-human primates from lethal disease
9. Unique dual target specificity of kinase inhibitor key for success against cancer
10. Serotonin, acting in a specific brain region, promotes sleep in fruit flies
11. A new male-specific gene in algae unveils an origin of male and female
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology: